A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

NCT04062669 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Virus Diseases

Interventions

BIOLOGICAL: Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
BIOLOGICAL: Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
BIOLOGICAL: Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
BIOLOGICAL: Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
DRUG: Saline Placebo
BIOLOGICAL: RabAvert

Sponsor

GlaxoSmithKline